ABSTRACT
Background Routine chest computed tomography angiography (CTA) is the primary imaging modality for thoracic aortic disease, yet cardiac information within these examinations remains underutilized. We evaluated whether left ventricular myocardial mass (LVMM) can be reliably quantified from routine non–electrocardiographically (ECG)-gated chest CTA and its application in thoracic aortic pathology.
Methods CTA scans were obtained from 257 patients without aortic disease and 181 patients with thoracic aortic aneurysm or dissection. LVMM was quantified using automated three-dimensional segmentation. In a separate 10-patient validation cohort, LVMM was compared across end-systolic, end-diastolic, and non-ECG-gated source reconstructions. CTA-derived LVMM was compared with published echocardiographic and cardiovascular magnetic resonance (CMR) reference values using Cohen’s d.
Results LVMM remained stable across cardiac phases and non-ECG-gated images (mean coefficient of variation, 2.4%), whereas left ventricular volume varied substantially (36.9%). CTA-derived LVMM demonstrated small effect sizes with the Penn method (d = 0.22) and moderate effect sizes with ASE linear (d = 0.67), area-length (d = 0.68), and CMR (d = 0.63). LVMM increased through young adulthood, with minimal association with age beyond 30 years. LVMM was comparable between patients with thoracic aneurysms and normal adults (140 ± 43 g vs. 141 ± 40 g; adjusted p = 1.0) but significantly greater in acute (199 ± 61 g) and chronic (191 ± 57 g) aortic dissection (both adjusted p < 0.001).
Conclusions Routine non-ECG-gated chest CTA enables reliable automated LVMM quantification without additional imaging or radiation and may facilitate large-scale investigations of ventricular remodeling in thoracic aortic disease.
Competing Interest Statement
KCT, DJ, JAP, LL, and LP have no conflicts of interest. JS has been paid a consulting fee by AstraZeneca and Pfizer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of University of Chicago gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ASE
- American Society of Echocardiography
- CTA
- computed tomography angiography
- CMR
- cardiovascular magnetic resonance
- LVMM
- left ventricular myocardial mass
- LVV
- left ventricular volume
- TEVAR
- thoracic endovascular aortic repair





